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ess: heikki.koskela@kuhSummary Assessment of the bronchodilation response to short-acting b2-adrenor-
eceptor agonists on pharmacologically induced bronchoconstriction has often been
used to investigate airway smooth muscle b2-adrenoreceptor function. However,
little is known about factors affecting this response. In the present study, the
bronchodilation response to 0.2mg of salbutamol on histamine-induced broncho-
constriction was assessed in 101 steroid-naı¨ve asthmatic subjects. The associations
of the response with a wide range of challenge procedure-related variables, clinical
asthma severity indicators, and blood markers of airway inflammation were
investigated. The response was re-assessed after 6 and 12 weeks’ therapy with
inhaled budesonide. Baseline FEV1, final histamine concentration, and the maximal
fall in FEV1 explained 35–59% of the total variation in the response to salbutamol,
depending on the index chosen to express the response. Serum concentration of
myeloperoxidase, an index of neutrophilic inflammation, was associated with a poor
response. The preceding week daily PEF variation, rescue bronchodilator use,
severity of asthmatic symptoms, blood eosinophil count, and serum eosinophilic
cationic protein and eosinophilic protein X concentrations were not associated with
the response. The salbutamol response seemed to diminish during budesonide
treatment but when adjusted by the challenge procedure-related variables the
treatment effect vanished. In conclusion, the bronchodilation response to
salbutamol on histamine-induced bronchoconstriction is largely determined byElsevier Ltd. All rights reserved.
173311; fax: +358 17 172683.
.fi (H.O. Koskela).
ARTICLE IN PRESS
Response to salbutamol 1761challenge procedure-related variables. It seems to be unrelated to the clinical
severity of asthma and is not affected by treatment with inhaled corticosteroids.
Neutrophilic airway inflammation may be associated with a poor response.
& 2006 Elsevier Ltd. All rights reserved.Introduction
The bronchodilation response to short-acting
b2-adrenoreceptor agonists (SABA) can be used to
assess airway b2-adrenoreceptor function in vivo. It
is difficult to assess in stable asthmatic patients in
whom there is usually no resting bronchoconstric-
tion.1,2 Therefore, it has become popular to assess
the bronchodilator effect of SABAs on induced
bronchoconstriction, especially in studies investi-
gating the development of bronchodilator toler-
ance to SABAs during regular treatment with
b2-adrenoreceptor agonists.
3–10 The bronchocon-
striction has usually been induced pharmacologi-
cally3–8,11 or, less often, by exercise.9,10
Given the popularity of the method, surprisingly
little is known about the factors associated with
the bronchodilation response to SABAs on pharma-
cologically induced bronchoconstriction. In most of
the above-mentioned studies one or all of the
following challenge procedure-related factors have
usually been considered: baseline lung function
(usually expressed as forced expiratory volume in 1 s,
FEV1), maximal fall in FEV1, and the dose/concen-
tration of the stimulus to produce the fall.
However, the number of subjects in the treatment
arms has usually been small.3–8 In addition, most of
these studies have been cross-over in design and
monitoring changes in the bronchodilation response
rather than measuring bronchodilation response as
an absolute variable. Therefore, variables that
are not related to the test have rarely been
included in the analysis. Such variables could be
the various subject characteristics, severity of the
subjects’ asthmatic symptoms, as well as markers
of asthmatic inflammation. Furthermore, knowl-
edge about the effect of inhaled corticosteroids on
the bronchodilation response to SABAs on pharma-
cologically induced bronchoconstriction is limited.
This information is relevant as corticosteroids are
now a routine part of the asthma management.12,13
In the present study, the variables associated
with the bronchodilation response to salbutamol on
histamine-induced bronchoconstriction were deter-
mined in a large group of carefully characterised,
steroid-naı¨ve asthmatic subjects. In addition, the
effect of inhaled budesonide treatment on this
response was assessed. The results of the presentstudy may help future investigators who intend to
use the bronchodilation response to SABAs on
pharmacologically induced bronchoconstriction in
order to assess airway b2-adrenoreceptor function.Methods
Study design
The present analysis is based on a patient popula-
tion which was recruited for a randomised, paral-
lel-group, double-blind study comparing two doses
(200 or 800 mg per day) of inhaled budesonide
(Pulmicort Turbuhalers, Astra Draco, Lund, Swe-
den) during a study period of 12 weeks, with a run-
in period of 1 week.14 Detailed information about
the methods and subjects is expressed in that
publication. The present analysis was divided to
two parts. First, the variables associated with the
bronchodilation response to salbutamol on hista-
mine-induced bronchoconstriction were analysed
using the baseline data. Second, the effect of
budesonide on this response was assessed by
comparing the baseline data with the data obtained
during the budesonide treatment. Since the two
budesonide doses were shown to attenuate the
histamine responsiveness similarly,14 the two treat-
ment arms were analysed together.Measurements
Skin prick tests were performed against common
aeroallergens and atopy was defined as at least
3mm wheal reaction to any of the allergens.15
During the study the patients continuously re-
corded their peak expiratory flow rates (PEF)
before they took their medication in the morning
and in the evening (Mini Wright Peak Flow Meter,
Clement Clark International, London, UK), their
rescue SABA use, as well as adverse reactions. They
also recorded their symptoms of asthma separately
each day and night as a single score from 0 to 3
(0 ¼ no symptoms, 3 ¼ severe symptoms). Hista-
mine responsiveness was assessed three times,
during the run-in phase, and after 6 and 12 weeks’
treatment. Blood samples were collected four
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Figure 1 Indices that were used to express the bronch-
odilation response to salbutamol on histamine-induced
bronchoconstriction. Both the ‘broncho-dilation’ and the
‘residual bronchoconstriction’ were expressed as percen-
tage of the post-saline FEV1.
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12 weeks’ treatment and the following analyses
were performed: The total eosinophil count was
calculated by routine differential counting with a
Coulter Counter (Coulter STKS, Coulter Electronics
Ltd., Luton, UK). The serum eosinophilic cationic
protein (ECP), serum eosinophilic protein X (EPX)
and serum myeloperoxidase (MPO) were measured
with commercially available radioimmunoassay
research kits (Pharmacia Diagnostics, Uppsala,
Sweden).
Subjects
One hundred and five adult patients with recently
diagnosed asthma were recruited (asthma diag-
nosed during the last 3 months preceding the study
and the symptoms presenting for less than 6
months). One hundred and one patients underwent
all the baseline measurements. Ninety-seven pa-
tients completed the 12-week treatment period. At
baseline, all the patients had to be without regular
pharmacological treatment for their asthma and
they were allowed only SABAs for rescue treat-
ment. All the patients fulfilled the criteria of
asthma by the American Thoracic Society16 and
showed airway hyperresponsiveness (provocative
concentration of histamine to induce a 20% fall in
FEV1 (PC20) less or equal to 8mg/ml). Of the 101
patients at baseline, there were 36 men, 27 current
smokers, and 68 atopic subjects. The subjects were
mean (SD) 38 (12) years old and their FEV1 was 87
(10) % of predicted.17 The daily number of short-
acting b2-agonist rescue inhalations was 1.4 (1.7)
during the run-in phase and only ten subjects (9.9%)
used equal or more than four inhalations per day.
Signed informed consent was obtained from all
subjects and the study was approved by the Ethics
Committee of Kuopio University Hospital.
Histamine challenge and definitions of the
salbutamol response indices
The subjects had refrained from taking SABAs for at
least 8 h before the challenge. The airway respon-
siveness to histamine was assessed using a mod-
ification of the method by Cockcroft et al.,18
differing from the original in that a dosimetric
nebuliser (Spira Elektro 2, Hengityshoitokeskus,
Ha¨meenlinna, Finland) was used. The first nebu-
lised solution was 0.9% saline and the post-saline
FEV1 was taken as the baseline value. After
that, histamine was inhaled in doubling concentra-
tions from 0.03 up to 16mg/ml. The challenge
was terminated when a fall X20% in FEV1 wasdocumented or when the maximal histamine con-
centration had been administered.
The percentage fall in FEV1 after the final
histamine concentration was recorded and defined
as the maximal fall. Then the subjects inhaled
0.2mg of salbutamol from a metered-dose inhaler
(Ventolines, GlaxoWellcome, London, UK). The
FEV1 was measured in duplicate 5min thereafter,
and the better of the two values was used for the
analysis. Two indices were used to express the
bronchodilation response to salbutamol on hista-
mine-induced bronchoconstriction (Fig. 1): The
‘bronchodilation’ was the increase in FEV1 from
the maximal fall value to the post-salbutamol
value, expressed as percentage of the baseline
value.5 The ‘residual bronchoconstriction’ was the
percentage change in FEV1 from the baseline value
at 5min after salbutamol inhalation,7 with a
negative value indicating a smaller FEV1 value at
5min post-salbutamol compared with the post-
saline value.Statistical analysis
The deviation of the distribution of the salbutamol
response indices from a normal distribution was
studied by the one-sample Kolmogorov–Smirnov
test. To define the variables associated with the
bronchodilation response to salbutamol on hista-
mine-induced bronchoconstriction at baseline, an
analysis of covariance with backwards directed
stepwise procedure was used. The response vari-
ables were the bronchodilation and the residual
bronchoconstriction. The explanatory variables
were the baseline FEV1 (expressed as % of the
predicted17), the final histamine concentration
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mine-induced maximal fall in FEV1, sex, age,
smoking pack-years, presence of current smoking,
presence of atopy, the mean daily number of short-
acting b2-agonist rescue inhalations during the
preceding week, the mean daily symptom score
during the preceding week, the mean daily PEF
variation during the preceding week, blood eosino-
phil count, ECP, EPX, and MPO. The first three
explanatory variables were defined as test-related
variables since they were related to the histamine
challenge procedure. To define the variables
associated with the serum MPO, a similar analysis
of covariance was performed. The adjusted and
unadjusted changes over time in salbutamol re-
sponse were examined applying mixed models.19
The test-related variables were used as time-
varying covariates in the analysis of adjusted
change in the bronchodilation and the residual
bronchoconstriction.
The data were presented as means and 95%
confidence intervals. P-values less than 0.05
were considered statistically significant. The sta-
tistical analyses were performed using SPSS for
Windows 11.5.Results
The factors associated with the
bronchodilation response to salbutamol on
histamine-induced bronchoconstriction at
baseline
Both the bronchodilation and the residual bronch-
oconstriction showed a close-to-normal distribution
within the study population. The following vari-
ables were statistically significantly associated with
bronchodilation (P-value, percentage explained
from the total variation in bronchodilation, and
the direction of association): baseline FEV1
(P ¼ 0:018, 2.4%, the larger the baseline FEV1,
the smaller the bronchodilation), final histamine
concentration (Po0:001, 20.8%, the larger the
histamine concentration, the smaller the broncho-
dilation), maximal fall (Po0:001, 34.8%, the larger
the fall, the larger the bronchodilation), and MPO
(P ¼ 0:017, 2.5%, the larger the MPO, the smaller
the bronchodilation).
The following variables were associated with the
residual bronchoconstriction: baseline FEV1
(P ¼ 0:016, 3.7%, the larger the baseline FEV1,
the larger the residual bronchoconstriction), final
histamine concentration (Po0:001, 31.7%, the
larger the histamine concentration, the larger theresidual bronchoconstriction), and MPO (P ¼ 0:011,
4.2%, the larger the MPO, the larger the residual
bronchoconstriction).
The preceding week daily PEF variation, rescue
SABA use, severity of asthmatic symptoms, blood
eosinophil count, and serum ECP and EPX concen-
trations were not associated with the salbutamol
response indices.
Since serum level of MPO was the only test-
unrelated variable that was associated with the
salbutamol response indices, its determinants were
also defined. The following variables were statisti-
cally significantly associated with MPO (P-value,
percentage explained from the total variation in
MPO, and the direction of association): current
smoking (P ¼ 0:005, 3.7%, MPO values were larger
in current smokers than in never- or ex-smokers),
blood eosinophil count and serum ECP (due to their
strong interrelationship they were analysed to-
gether; Po0:001, 54.2%, the larger the values, the
larger the MPO).The effect of a 12-week treatment with
inhaled budesonide on the bronchodilation
response to salbutamol on histamine-
induced bronchoconstriction
When analysing unadjusted data, there were
significant changes in both salbutamol response
indices. After a 12-week treatment with budeso-
nide the bronchodilation decreased from 24.7
(23.1–26.3)% to 20.9 (19.3–22.5)%, Po0:001, and
the residual bronchoconstriction changed from
1.5 (2.8 to 0.2)% to 3.8 (5.2 to 2.5)%,
P ¼ 0:001.
However, there were also significant changes in
the test-related variables that were shown to be
associated with the salbutamol response indices:
The baseline FEV1 (% of predicted) increased 2.1%
(P ¼ 0:002), the final histamine concentration
increased 1.0 doubling doses (Po0:001), and the
maximal fall decreased 1.5% (though not statisti-
cally significantly, P ¼ 0:14). The MPO values
increased from 463 (419–509) mg/l before treat-
ment to 518 (473–567) mg/l after treatment
(P ¼ 0:02). The treatment-induced change in both
salbutamol response indices was statistically sig-
nificantly associated with the changes in the base-
line FEV1 (P ¼ 0:01), final histamine concentration
(Po0:001) and the maximal fall (Po0:001). How-
ever, the treatment-induced change in the salbu-
tamol response indices did not associate with the
treatment-induced changes in MPO (P ¼ 0:36).
When the bronchodilation and the residual
bronchoconstriction were adjusted with the
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Figure 2 Effect of budesonide on bronchodilation (a) and
residual bronchoconstriction (b). Closed circles indicate
unadjusted values whereas the open circles indicate
values that are adjusted with baseline FEV1, final
histamine concentration, and maximal fall in FEV1.
H.O. Koskela et al.1764test-related variables, the differences between
pre-treatment, 6-week post-treatment and 12-
week post-treatment values completely disap-
peared (P ¼ 0:32 for both salbutamol response
indices, Fig. 2). This result indicates that the
changes in the bronchodilation and the residual
bronchoconstriction were mainly explained by the
changes in the test related variables. The results
did not change if the two treatment groups were
analysed separately and there was no difference
between the treatment groups.Discussion
The present study shows that the bronchodilation
response to salbutamol on histamine-induced
bronchoconstriction is largely determined by vari-ables that are directly related to the histamine
challenge procedure itself, namely the baseline
lung function, the final histamine concentration,
and the maximal fall in FEV1. These variables
explained 35–59% of the total variation in the
salbutamol response, depending on the index
chosen. Most variables that were unrelated to the
challenge procedure, including various subject
characteristics, clinical asthma severity indicators,
and eosinophilic inflammation variables were not
associated with the response. Indeed, the only
challenge-unrelated variable that showed a signifi-
cant association with the salbutamol response was
the serum concentration of MPO, an index of
neutrophilic inflammation.20 The present study also
shows that treatment with inhaled budesonide does
not affect the salbutamol response when the
treatment-induced changes in baseline FEV1, final
histamine concentration, and maximal fall in FEV1
are taken into account.
Studies about the effect of regular treatment
with b2 adrenergic agonists on the bronchodilator
effect of SABAs on pharmacologically induced
bronchoconstriction3–8 have often suggested the
same test-related variables as the present study.
Compared with these studies, the present study
includes a considerably larger study group and
more detailed information about the various sub-
ject characteristics, asthma severity indicators,
and markers of asthmatic inflammation. Therefore,
the present authors can estimate the relative
contribution of the test-related variables and
asthma severity-related variables. The results
clearly show that the bronchodilation response to
salbutamol on histamine-induced bronchoconstric-
tion is mainly determined by directly test-related
variables. One may criticise that some of the test-
related variables, like FEV1 at baseline and the final
histamine concentration also measure asthma
severity. However, the authors believe that their
association with the salbutamol response is techni-
cal by nature since the great majority of test-
unrelated asthma severity indicators showed no
association. Thus, the documented association of
high FEV1 before challenge with poor salbutamol
response probably does not indicate that mild
asthma would be associated with a poor response
to b2 adrenergic agonists but that there is limited
‘‘room’’ for FEV1 improvement. Accordingly, the
association of high final histamine concentration
with poor salbutamol response does not indicate
that mild airway hyperresponsiveness would be
associated with a poor response to b2 adrenergic
agonists but that the competition between bronch-
oconstrictor and bronchodilator effects on airway
smooth muscle is probably in favour of the former.
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dure-unrelated variable that was associated with
the salbutamol response: the serum concentration
of MPO. Induced sputum neutrophil count corre-
lates well with the sputum MPO level in asthma21,22
and MPO is widely used as an index of neutrophilic
inflammation.20 In the present study, MPO was
measured from serum and it is difficult to estimate
how well it reflects the neutrophilic inflammation
within the airways. In previous studies those
asthmatic subjects with a predominantly neutro-
philic airway inflammation have shown a poor
increase in FEV1 after a course with either
inhaled22,23 or oral22 corticosteroids suggesting that
neutrophilic inflammation may be involved in the
pathophysiology of irreversible airflow obstruction
in asthma. Assuming that serum MPO does reflect
the neutrophilic inflammation within the airways,
the present study is the first to suggest that
neutrophil-dominated airway inflammation may
also be associated with a poor bronchodilation
response to salbutamol on induced broncho-
constriction.
In the present population, serum MPO level
correlated closely with the indices of eosinophilic
inflammation and, much less clearly, with current
smoking. It has been shown previously that in
severe asthma, eosinophils and neutrophils are
usually found together in the airways24 and that
smoking induces neutrophilic airway inflammation
in mild asthma.25 Taken together, these findings
suggest that neutrophilic airway inflammation is
typical for an asthmatic patient with severe
eosinophilic airway inflammation, and may be
enhanced by smoking. Interestingly, neither indices
of eosinophilic inflammation nor smoking habits
were independent determinants of the salbutamol
response, highlighting the role of neutrophilic
inflammation in this respect.
Treatment with budesonide did not affect the
bronchodilation response to salbutamol on hista-
mine-induced bronchoconstriction though it had
clear effects on the patient’s asthmatic symptoms,
lung function, histamine responsiveness, and in-
dices of eosinophilic inflammation (as previously
reported by Tukiainen et al.14). This fits to the
above-mentioned concept that this response to
salbutamol has little to do with the clinical severity
of patient’s asthma. The lack of effect by budeso-
nide on the salbutamol response may also be
explained by the fact that inhaled corticosteroids
do not suppress the airway neutrophilic inflamma-
tion whereas their effect on eosinophilic inflamma-
tion is clear.26,27 In fact, the serum MPO levels
actually increased during the budesonide treat-
ment in the present study. This could be explainedby the fact that corticosteroids can inhibit neu-
trophil apoptosis and phagocytic removal and yet
induce the same process in eosinophils.28,29
Limitations of the study
One may criticise that the observation time after
the salbutamol dose (5min) was too short to fully
reveal the salbutamol response. However, the
baseline histamine challenge showed that the
FEV1 was just 1.5% lower at 5min post-salbutamol
compared with the post-saline FEV1 (the ‘residual
bronchoconstriction’). The authors therefore be-
lieve that a longer observation time would not have
changed the results significantly. In fact, the rather
short observation time after salbutamol ensured
that the spontaneous recovery after histamine
challenge (30–60min in adults30) did not interfere
with the salbutamol response. The authors’ way to
measure inflammatory indices from blood samples
instead of sputum samples may also be considered
as a weakness. However, by this way the authors
could measure these indices in all subjects whereas
as many as a quarter of subjects may produce
inadequate samples in response to sputum induc-
tion,31 which can be a cause of a selection bias.
Finally, as the present study was not placebo-
controlled, the authors cannot define whether the
documented increase in MPO during budesonide
treatment was a true treatment effect.Conclusion
In conclusion, the bronchodilation response to
salbutamol on histamine-induced bronchoconstric-
tion seems to be mainly determined by test-related
technical variables. This response is unrelated to
the clinical severity of asthma and is not affected
by treatment with inhaled budesonide. Neutrophi-
lic airway inflammation may be associated with a
poor response.Acknowledgements
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